Table 1.

Clinical characteristics of the 178 patients by treatment received for whom an observed pathologic tumor response and molecular prediction of tumor response are available

Clinical and pathologic characteristicsPatients received T/FACPatients received FACP
No. patients(%)No. patients(%)
No. patients9151.18748.9
pCR1920.978.00.02
RD7279.18092.00.02
Race0.42
    White4044.04147.1
    Black99.944.6
    Hispanic4145.14248.3
    Asian11.100.0
Mean age, y (range)51.5 (26-73)50.3 (31-74)0.41
Menopausal status0.63
    Premenopausal4650.54855.2
    Postmenopausal4448.43843.7
    Unknown11.111.1
Histology0.11
    Ductal81898396.7
    Lobular66.611.1
    Mixed44.422.2
Clinical T size0.89
    T0-T188.855.7
    T23942.83742.6
    T31920.91820.7
    T42527.52629.9
    Unknown00.011.1
Clinical N stage0.76
    N03134.12832.3
    N13841.73337.9
    N2-32224.22528.7
    Unknown00.011.1
Grade*0.45
    1101155.7
    230333135.6
    33639.53641.5
    Unknown1516.51517.2
ER status0.85
    Negative4246.23843.7
    Positive4953.84955.7
PR status0.98
    Negative4953.84652.9
    Positive4246.24147.1
HER2 status0.35
    Not overexpressed7582.47788.5
    Overexpressed1617.61011.5
Patients underwent ALND or SLNB8492.381930.93
Mean no. LN removed (range)15.8 (1-38)15.8 (1-43)0.97
Patients with ALN involvement46/8446/810.9
Type of surgery0.99
    Breast conservation1112.11112.6
    Mastectomy6672.56574.8
    Surgery not done due to PD66.666.9
    Unknown88.855.7

Abbreviations: LN, lymph node; ALN, axillary lymph node; ALND, axillary lymph node dissection; SLNB, sentinel lymph node biopsy; PD, progressive disease.

  • *Histologic grade according to the modified Black's nuclear grade.

  • Status for ER and PR was determined by immunohistochemistry.

  • Status for HER2 was determined by immunohistochemistry or fluorescence in situ hybridization.